Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology and medical device company centered on precision fluid management for patients with cardio-renal conditions and fluid overload. News about Nuwellis frequently highlights clinical data, regulatory milestones, pediatric innovation, and business updates related to its Aquadex SmartFlow® ultrafiltration system and its Vivian™ pediatric continuous renal replacement therapy (CRRT) platform in development.
Readers of this NUWE news page can follow company announcements on topics such as new patents for extracorporeal safety technologies, NIH grant-supported development of the Vivian pediatric system, and multi-center registries like ULTRA-Peds that examine real-world Aquadex use in critically ill children. Nuwellis also issues news about clinical experiences at hospitals, including studies presented at nephrology conferences that explore Aquadex applications in acute kidney injury, post-cardiac-surgery fluid overload, and complex critical-care cases.
In addition to clinical and technology updates, Nuwellis regularly reports quarterly financial results, at-the-market equity offering arrangements, and other material events through press releases and SEC-referenced communications. These updates provide insight into revenue trends, product launches such as new catheter sizes or circuits, and strategic steps like focusing on U.S. market growth.
Investors, clinicians, and researchers can use this news feed to track how Nuwellis is advancing its Aquadex platform, expanding into pediatric and hospital-based outpatient settings, and progressing the Vivian pediatric CRRT system. Returning to this page allows users to monitor ongoing developments in the company’s cardio-renal strategy, intellectual property portfolio, and regulatory and clinical milestones associated with NUWE.
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company, is set to release its Q1 2023 financial results on May 9, 2023. The company will hold a conference call and webcast at 9:00 AM ET to discuss the financial results and provide a general business overview. Investors can access the live webcast on Nuwellis' Investors page or by calling the designated numbers provided for U.S. and international participants.
Nuwellis specializes in treating fluid overload issues with its Aquadex SmartFlow® system, aimed at transforming the lives of affected patients. This system is designed for use in both outpatient and inpatient settings under physician supervision.
Nuwellis, Inc. (Nasdaq: NUWE) recently announced a peer-reviewed publication supporting ultrafiltration as a viable treatment for acute decompensated heart failure (ADHF), particularly for patients unresponsive to diuretics. The publication, featured in Cardiorenal Medicine Journal, reviewed data from seven trials involving 771 patients, highlighting ultrafiltration's advantages in efficient fluid removal without harming renal function. This method could reduce hospital readmissions and alleviate healthcare costs associated with ADHF. Nuwellis aims to establish ultrafiltration as the standard of care through increased awareness and clinical evidence.
Nuwellis, Inc. (Nasdaq: NUWE) announced that the Company’s independent directors approved equity awards on February 23, 2023, under the 2021 Inducement Plan. These awards were granted as material inducements for six new hires. The equity awards consist of options to purchase a total of 2,514 shares at an exercise price of $8.27 per share, equal to the closing stock price on the grant date. The options have a ten-year term and vest over four years, with 25% vesting after one year and the remainder vesting monthly, contingent on ongoing employment.
Nuwellis focuses on the Aquadex SmartFlow system for treating fluid overload in patients.
Nuwellis, Inc. (NASDAQ: NUWE) reported a 42% increase in Q4 revenue, reaching $2.3 million, while full-year revenue grew by 8% to $8.5 million for 2022. The company achieved a gross margin of 56.9% in Q4, up 250 basis points year-over-year. Key segments included Pediatrics (92% growth), Heart Failure (47% growth), and Critical Care (24% growth). Nuwellis entered an exclusive licensing agreement for the Selective Cytopheretic Device to treat pediatric Acute Kidney Injury. Peer-reviewed data demonstrated significant improvements in hospitalizations related to heart failure and kidney replacement therapy survival rates. The company ended 2022 with $18.3 million in cash.
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology firm, announced its participation in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023. Nestor Jaramillo, President and CEO, and Lynn Blake, CFO, will present at 9:20 AM ET and hold investor 1x1 meetings. The presentation will be available via a webcast on the company's website, where it will also be archived for later access. Nuwellis focuses on transforming patient care for those with fluid overload through its Aquadex SmartFlow® system, aimed at providing effective ultrafiltration therapy.
Nuwellis, Inc. (Nasdaq: NUWE) emphasizes the significance of maintaining intravascular volume during cardiac procedures in response to a recent editorial in The Annals of Thoracic Surgery. The editorial highlights ultrafiltration's role in preventing cardiac surgery-associated acute kidney injury (CSA-AKI), noting that up to 80% of patients may experience stage 1 or greater CSA-AKI. The authors challenge the reliance on diuretics, advocating for ultrafiltration as a viable alternative, particularly for patients resistant to diuretics. Dr. John Jefferies from Nuwellis expresses optimism regarding the validation of their Aquadex® technology, supported by data showing a 100% survival rate in a study involving high-risk CABG patients.
Nuwellis, Inc. (Nasdaq: NUWE) announced its fourth quarter and full year 2022 financial results will be released on February 28, 2023. A conference call and webcast is scheduled for 8:30 AM ET on the same day, where management will discuss the results and provide a business overview. The company focuses on addressing fluid overload through its Aquadex SmartFlow system, which employs ultrafiltration therapy. Nuwellis is headquartered in Minneapolis and has a subsidiary in Ireland. For live access, visit their Investors page.
Nuwellis, Inc. (Nasdaq: NUWE) reported preliminary unaudited revenues of approximately $2.3 million for Q4 2022 and $8.5 million for the full year, marking increases of 42% and 8% from the previous year. This growth is attributed to a strengthened sales strategy and market expansion beyond heart failure patients, with Pediatrics, Heart Failure, and Critical Care segments showing notable increases of 92%, 47%, and 24%, respectively. CEO Nestor Jaramillo emphasized their commitment to establishing the Aquadex SmartFlow® system as the standard for fluid overload treatment.
Nuwellis (Nasdaq: NUWE) has appointed Dr. John Jefferies as its new Chief Medical Officer, enhancing its leadership team as it pushes forward with clinical evidence supporting ultrafiltration for fluid overload patients. Dr. Jefferies, who brings over 20 years of cardiology expertise, will guide clinical and medical affairs and aid corporate development. He is currently the Chief of Cardiology at the University of Tennessee and has been part of Nuwellis' medical advisory board since 2019. This leadership change is expected to strengthen Nuwellis' position in the market.
Nuwellis, Inc. (Nasdaq: NUWE) held a special meeting of stockholders on January 4, 2023, where shareholders approved the Warrant Proposal to issue up to 66,226,752 common shares upon exercise of warrants from the October 2022 offering. A total of 3,815,782 shares, representing 36% of outstanding shares, were present. Votes tallied included 1,955,994 in favor and 1,791,220 against the proposal. Additionally, 1,971,645 votes were cast to authorize adjournments for further proxy solicitation if needed. The company focuses on treating fluid overload through its Aquadex SmartFlow system.